Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148421 | 0.76 | PKM (0.48) | PKM | |
| SCHEMBL23333268 | 0.76 | PKM (0.48) | PKM | |
| SCHEMBL2126658 | 0.76 | PKM (0.48) | PKM | |
| SCHEMBL1150449 | 0.76 | PKM (0.48) | PKM | |
| Adamantane SCHEMBL8487115 | 0.74 | PKM (0.46) | PKMHSD11B1 | |
| Methane SCHEMBL6564041 | 0.74 | PKM (0.46) | PKMHSD11B1 | |
| Hydrochloric Acid SCHEMBL4717994 | 0.74 | LMNA (0.47) | PKM | |
| SCHEMBL31665947 | 0.74 | PKM (0.46) | PKMHSD11B1 | |
| Ammonia Solution, Strong SCHEMBL572798 | 0.74 | PKM (0.46) | PKMHSD11B1 | |
| SCHEMBL5512268 | 0.74 | PKM (0.46) | PKMHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | claimed |
| US-8907096-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-12-09 | — | — | US | claimed |
| US-20140315905-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | VTV THERAPEUTICS LLC | 2014-10-23 | — | — | US | claimed |
| US-8835426-B2 | Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-16 | — | — | US | claimed |
| US-8809540-B2 | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-08-19 | — | — | US | claimed |
| EP-2125750-B1 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2014-05-21 | — | — | EP | claimed |
| US-20130231341-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-09-05 | — | — | US | claimed |
| US-8513430-B2 | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-20 | — | — | US | claimed |
| US-8383820-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | claimed |
| CN-102459158-A | Novel amide and amidine derivatives and use thereof | ABBOTT LAB | 2012-05-16 | — | — | CN | claimed |
| US-20120029029-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | US | claimed |
| WO-2012015715-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | WO | claimed |
| CN-101981026-A | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic use | SANOFI AVENTIS | 2011-02-23 | — | — | CN | claimed |
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | claimed |
| US-20100197675-A1 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2010-08-05 | — | — | US | claimed |
| EP-2125750-A2 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2009-12-02 | — | — | EP | claimed |
| EP-2064187-A2 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Vitae Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2008106128-A2 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | claimed |
| WO-2008024497-A2 | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| EP-4143185-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2023-03-08 | — | — | EP | disclosed |
| CN-115515953-A | Novel imidazolidinone derivatives as inhibitors of protein kinases, in particular DYRK1A, CLK1 and/or CLK4 | 珀哈制药公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2021219828-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2021-11-04 | — | — | WO | disclosed |
| EP-3904354-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2021-11-03 | — | — | EP | disclosed |
| CN-107556244-B | Fused ring compound, pharmaceutical composition and application thereof | 上海迪诺医药科技有限公司 | 2021-09-03 | — | — | CN | disclosed |
| EP-3259272-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | Shanghai de Novo Pharmatech Co., Ltd. (CN) | 2017-12-27 | — | — | EP | disclosed |
| WO-2016131380-A1 | FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO.,LTD. (CN) | 2016-08-25 | — | — | WO | disclosed |
| US-8927715-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8835426-B2 | Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1 | VITAE PHARMACEUTICALS, INC. (US) | 2014-09-16 | — | — | US | disclosed |
| EP-2125750-B1 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| CN-101787016-B | Pyridine carboxamides as 11-beta-hsd1 inhibitors | ASTRAZENECA AB | 2013-08-28 | — | — | CN | disclosed |
| US-8513430-B2 | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| CN-102603711-A | Pyridine carboxamides as 11-beta-hsd1 inhibitors | ASTRAZENECA AB | 2012-07-25 | — | — | CN | disclosed |
| CN-102459158-A | Novel amide and amidine derivatives and use thereof | ABBOTT LAB | 2012-05-16 | — | — | CN | disclosed |
| CN-101573336-B | Pyridine carboxamides as 11-beta-HSD 1 inhibitors | ASTRAZENECA AB | 2012-03-21 | — | — | CN | disclosed |
| US-8129423-B2 | 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; | HOFFMAN-LA ROCHE INC. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20120029029-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2012015715-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | WO | disclosed |
| CN-101351466-B | Heterocyclic Janus kinase 3 inhibitors | ASTELLAS PHARMA INC | 2011-08-10 | — | — | CN | disclosed |
| CN-102066335-A | Substituted pyrimidin-5-carboxamides 281 | ASTRAZENECA AB | 2011-05-18 | — | — | CN | disclosed |
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| CN-101981026-A | Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic use | SANOFI AVENTIS | 2011-02-23 | — | — | CN | disclosed |
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. | 2011-02-10 | — | — | US | disclosed |
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100197675-A1 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. | 2010-08-05 | — | — | US | disclosed |
| CN-101787016-A | Pyridine carboxamides as the 11-beta-HSD 1 inhibitors | ASTRAZENECA AB | 2010-07-28 | — | — | CN | disclosed |
| US-7728029-B2 | Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-2125750-A2 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | Vitae Pharmaceuticals, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| CN-101573336-A | Pyridine carboxamides as 11-beta-HSD 1 inhibitors | ASTRAZENECA AB (SE) | 2009-11-04 | — | — | CN | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| EP-2104665-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. Hoffmann-Roche AG (CH) | 2009-09-30 | — | — | EP | disclosed |
| EP-2064187-A2 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Vitae Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| CN-101351466-A | Heterocyclic Janus kinase 3 inhibitors | ASTELLAS PHARMA INC (JP) | 2009-01-21 | — | — | CN | disclosed |
| EP-2010479-A1 | 11 BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008106128-A2 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2008-05-01 | — | — | US | disclosed |
| WO-2008046758-A2 | IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-24 | — | — | WO | disclosed |
| EP-1910369-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | Astellas Pharma Inc. (JP) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008024497-A2 | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2007115935-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | ANDERSON KEVIN WILLIAM | 2007-09-27 | — | — | US | disclosed |
| WO-2007013673-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-02-01 | — | — | WO | disclosed |
| WO-2007013673-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225280-A1 | Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase | HSD3B2, HSD3B1, HSD17B2 | PKM 1302/4885HSD11B1 6/4885 |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | PKM 2041/4885HSD11B1 2/4885 |
| US-20110034455-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | PKM 1597/4885HSD11B1 1/4885 |
| US-20080103183-A1 | NEW IMIDAZOLONE AND IMIDAZOLIDINONE DERIVATIVES AS 11B-HSD1 INHIBITORS | HSD11B1, HSD17B1, HSD17B11 | PKM 971/4885HSD11B1 1/4885 |
| US-20100197675-A1 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD3B1, HSD11B2 | PKM 2564/4885HSD11B1 1/4885 |
| US-20120029029-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HSD11B1, HSD11B2, HSD3B1 | PKM 362/4885HSD11B1 1/4885 |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | PKM 278/4885HSD11B1 2758/4885 |
| US-20130231341-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | PKM 2493/4885HSD11B1 1/4885 |
| US-20140315905-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | PKM 2493/4885HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.